Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Market price (% of par)
-
85.44%
-
Total 13F principal
-
$197,744,550
-
Principal change
-
-$14,608,692
-
Total reported market value
-
$176,846,616
-
Number of holders
-
22
-
Value change
-
+$6,712,325
-
Number of buys
-
12
-
Number of sells
-
15
Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q3 2024
As of 30 Sep 2024,
REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 was held by
22 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$197,744,550
in principal (par value) of the bond.
The largest 10 bondholders included
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC), Graham Capital Management, L.P., Nuveen Asset Management, LLC, GLAZER CAPITAL, LLC, D. E. Shaw & Co., Inc., AQR Arbitrage LLC, CITIGROUP INC, JPMORGAN CHASE & CO, AMUNDI, and MORGAN STANLEY.
This page lists
22
institutional bondholders reporting positions
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.